Food Safety Incidents

Suggestion of therapeutic properties has been detected in Dietary supplement ozemzinh the.

Written by SGS Digicomply Editorial Team | Feb 27, 2026 11:00:00 PM

Incident Report: Dietary Supplement Safety Concern

On February 12, 2026, a significant food safety incident was reported concerning a dietary supplement known as ozemzinh the. This incident originated in Brazil and has raised concerns regarding the therapeutic properties suggested by the product.

The Brazilian Health Regulatory Agency, known as ANVISA, has identified potential issues related to the claims made about the supplement's benefits. Such claims can mislead consumers and pose health risks if the product does not provide the stated effects or if it contains unapproved ingredients.

It is crucial for consumers to remain vigilant when considering dietary supplements, particularly those that suggest therapeutic benefits. Regulatory agencies play a vital role in ensuring that products on the market are safe and accurately labeled. In this case, the involvement of ANVISA highlights the importance of regulatory oversight in the dietary supplement industry.

Consumers are advised to consult with healthcare professionals before using any dietary supplement, especially those with claims that appear too good to be true. Additionally, it is essential to stay informed about any updates or recalls related to dietary supplements to ensure personal safety and well-being.

As this situation develops, further investigations and assessments by health authorities will be crucial in determining the safety and efficacy of the product in question.

  • Incident: Suggestion of therapeutic properties has been detected in Dietary supplement ozemzinh the.
  • Date: 2026-02-12
  • Product: Dietary supplement ozemzinh the
  • Market: Available to SGS Digicomply users only. Explore the platform (for enterprises, no individual plans)
  • Origin of issue: Brazil
  • Hazard: Available to SGS Digicomply users only. Explore the platform (for enterprises, no individual plans)
  • Incident Category: Control
  • Source: Brazilian Health Regulatory Agency - ANVISA